Home›Dipyridamole

Dipyridamole

Also known as: Dipyridamole

Platelet Aggregation Inhibitor

Route: Intravenous

Check Dipyridamole Interactions →
11 interactions on record

Dipyridamole has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Riociguat, Adenosine, Caffeine. Patients taking Dipyridamole should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
11
Contraindicated
1
Major
6
Moderate
2

Contraindicated (1)

Major (6)

  • Dipyridamole + Adenosine— Dipyridamole increases plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be nece…
  • Dipyridamole + Caffeine— Caffeine may abolish the coronary vasodilation induced by intravenous dipyridamole, potentially leading to false negativ…
  • Dipyridamole + Cladribine— Potent BCRP, ENT1, and CNT3 transporter inhibitor may alter cladribine bioavailability, intracellular distribution, and …
  • Dipyridamole + Enoxaparin Sodium— Platelet inhibitor that may enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct …
  • Dipyridamole + Regadenoson— Dipyridamole increases cardiovascular effects of regadenoson (adenosine A2A-receptor agonist). Risk of cardiovascular si…
  • Dipyridamole + Theophylline— Theophylline may abolish the coronary vasodilation induced by intravenous dipyridamole, potentially leading to false neg…

Moderate (2)

  • Dipyridamole + Heparin Sodium— Interferes with platelet aggregation and may induce bleeding. Use with caution; dose reduction of antiplatelet agent or …
  • Dipyridamole + Mao Inhibitors— Dipyridamole may counteract anticholinesterase effect of cholinesterase inhibitors, potentially aggravating myasthenia g…

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations